{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.10","upperLimit":"11.00","value":"4.0"},{"groupId":"OG001","lowerLimit":"1.20","upperLimit":"10.00","value":"4.0"}]}],"title":"Cycle 1 (n=346,190)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.10","upperLimit":"23.10","value":"0.1"},{"groupId":"OG001","lowerLimit":"0.50","upperLimit":"10.00","value":"3.0"}]}],"title":"Cycle 2 (n=361,178)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.10","upperLimit":"5.50","value":"0.1"},{"groupId":"OG001","lowerLimit":"1.00","upperLimit":"21.40","value":"2.8"}]}],"title":"Cycle 3 (n=349,177)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"2.50","value":"0.1"},{"groupId":"OG001","lowerLimit":"0.50","upperLimit":"8.00","value":"2.7"}]}],"title":"Cycle 4 (n=346,173)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"2.50","value":"0.1"},{"groupId":"OG001","lowerLimit":"0.10","upperLimit":"8.10","value":"2.6"}]}],"title":"Cycle 5 (n=332,165)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"2.50","value":"0.1"},{"groupId":"OG001","lowerLimit":"0.10","upperLimit":"20.00","value":"2.7"}]}],"title":"Cycle 6 (n=319,162)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"23.60","value":"0.1"},{"groupId":"OG001","lowerLimit":"0.50","upperLimit":"6.70","value":"2.7"}]}],"title":"Cycle 7 (n=304,156)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.00","upperLimit":"2.50","value":"0.1"},{"groupId":"OG001","lowerLimit":"0.10","upperLimit":"17.90","value":"2.55"}]}],"title":"Cycle 8 (n=305,152)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.10","upperLimit":"28.70","value":"4.7"},{"groupId":"OG001","lowerLimit":"1.20","upperLimit":"57.40","value":"19.00"}]}],"title":"Overall (n=368,201)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"369"},{"groupId":"OG001","value":"203"}],"units":"Participants"}],"description":"Duration of rituximab administration was defined as the time from start to end of the SC injection or IV infusion. The median duration was reported.","dispersionType":"Full Range","groups":[{"description":"Participants with previously untreated, CD20-positive DLBCL received up to 8 cycles of rituximab in combination with CHOP. Treatment was given on Day 1 of each cycle, and the cycle length (14 or 21 days) was decided by the study center. For Cycle 1, rituximab was administered at a dose of 375 mg/m\\^2 via IV infusion; subsequent doses were given as 1400 mg via SC injection. Tumor response was assessed after 4 cycles according to criteria published by Cheson et al (1999), which are presented in Outcome Measure 1. The duration of CHOP therapy could be reduced from 8 to 6 cycles for those who achieved CR or CRu after 4 cycles, but all participants received a full 8 cycles of rituximab.","id":"OG000","title":"Rituximab SC"},{"description":"Participants with previously untreated, CD20-positive DLBCL received up to 8 cycles of rituximab in combination with CHOP. Treatment was given on Day 1 of each cycle, and the cycle length (14 or 21 days) was decided by the study center. For all cycles, rituximab was administered at a dose of 375 mg/m\\^2 via IV infusion. Tumor response was assessed after 4 cycles according to criteria published by Cheson et al (1999), which are presented in Outcome Measure 1. The duration of CHOP therapy could be reduced from 8 to 6 cycles for those who achieved CR or CRu after 4 cycles, but all participants received a full 8 cycles of rituximab.","id":"OG001","title":"Rituximab IV"}],"paramType":"MEDIAN","populationDescription":"Safety Population; n = number of participants in the analysis for the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Cycles 1, 2, 3, 4, 5, 6, 7, and 8 (each cycle was 14 or 21 days)","title":"Median Duration of Rituximab Administration for Each Treatment Cycle","type":"SECONDARY","unitOfMeasure":"hours"}